Harmony Biosciences Inc.
HRMY | NASDAQ
$41.98
-$0.12 (-0.29%)
Sep 22, 2026, 11:17 AM ET · Market open
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Jeffrey Dayno | President, Chief Executive Officer & Director |
| Glenn Reicin | Chief Financial Officer |
| Peter Anastasiou | Chief Operating Officer |
| Adam Zaeske | Executive Vice President & Chief Commercial Officer |
| Andrew Serafin | Executive Vice President & Chief Strategy Officer |
| Brennan Doyle | Vice President & Head of Investor Relations |
| Christian Ulrich | Executive VP, General Counsel & Corporate Secretary |
| Jeffrey S. Aronin | Founder & Non-Executive Chairman |
| Kumar Budur | Executive Vice President and Chief Medical & Scientific Officer |
| Stephen Mollichella | Senior VP, Controller & Interim Principal Financial Officer |
| Tricia Glover | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 31, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 22, 2026 | 3 | Filing |
| Jul 16, 2026 | 8-K | Current Report |
| May 18, 2026 | 4 | Filing |
| May 18, 2026 | 3 | Filing |
| May 18, 2026 | 4 | Filing |
| May 18, 2026 | 4 | Filing |
Harmony Biosciences Inc.
| Country | United States |
| IPO Date | Aug 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 293 |
| CEO | Jeffrey Dayno |
Contact Details
630 West Germantown Pike Plymouth Meeting,
Pennsylvania 19462 United States
Stock Details
| Ticker Symbol | HRMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001802665 |
| CUSIP Number | 413197104 |
| ISIN Number | US4131971040 |
| SIC Code | 2834 |
Recent News
- 1 day ago / defenseworld.netInsider Selling: Harmony Biosciences (NASDAQ:HRMY) Insider Sells $34,400.00 in Stock
- 2 days ago / defenseworld.netKumar Budur Sells 1,800 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock
- 19 days ago / zacks.comWhy Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
- 1 month ago / defenseworld.netAurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY
- 1 month ago / marketbeat.comHarmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
- 2 months ago / seekingalpha.comHarmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated
- 2 months ago / zacks.comHRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
- 2 months ago / zacks.comHere is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now
- 2 months ago / seekingalpha.comHarmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript
- 2 months ago / marketbeat.comHarmony Biosciences Q2 Earnings Call Highlights
Add to Watchlist
Select watchlists to add or remove HRMY